| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric Cancer Patients Regardless of PD-L1 Status
April 7, 2024
SAN DIEGO – The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patie...